• 1. Chemical mechanism of the radical feedback loop in the classical BZ reaction. Malonyl bromite and oxalic acid as flow-through intermediates
  László Hegedüs,Horst-Dieter F?rsterling,Enik? Kókai,Krisztina Pelle,Gabriella Taba,Mária Wittmann,Zoltán Noszticzius Phys. Chem. Chem. Phys. 2000 2 4023

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Tricarboxylic acids and derivatives

Recent Advances in the Study of Ethane-1,1,2-tricarboxylic Acid (CAS: 922-84-9) and Its Applications in Chemical Biology and Medicine

Ethane-1,1,2-tricarboxylic acid (CAS: 922-84-9) is a tricarboxylic acid derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its three carboxyl groups, exhibits unique chemical properties that make it a valuable intermediate in synthetic chemistry and a candidate for drug development. Recent studies have explored its role in enzyme inhibition, metabolic pathways, and as a building block for more complex molecules. This research brief aims to summarize the latest findings related to ethane-1,1,2-tricarboxylic acid, highlighting its significance in the field.

One of the most notable areas of research involving ethane-1,1,2-tricarboxylic acid is its potential as an enzyme inhibitor. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits inhibitory activity against certain enzymes involved in the tricarboxylic acid (TCA) cycle, a critical metabolic pathway in eukaryotic cells. The study utilized molecular docking simulations and kinetic assays to elucidate the binding mechanisms of ethane-1,1,2-tricarboxylic acid to target enzymes, revealing its competitive inhibition profile. These findings suggest that this compound could serve as a lead structure for developing novel therapeutics targeting metabolic disorders.

In addition to its enzyme inhibitory properties, ethane-1,1,2-tricarboxylic acid has been investigated for its role in chelation therapy. A recent preprint on bioRxiv highlighted its ability to bind metal ions, such as iron and copper, with high affinity. This property is particularly relevant in the context of diseases characterized by metal ion overload, such as hemochromatosis and Wilson's disease. The study employed spectroscopic techniques, including UV-Vis and NMR, to characterize the metal-ligand complexes formed by ethane-1,1,2-tricarboxylic acid. The results indicated that this compound could potentially be modified to enhance its selectivity and efficacy as a chelating agent.

Another promising avenue of research involves the use of ethane-1,1,2-tricarboxylic acid as a precursor for the synthesis of more complex bioactive molecules. A 2022 paper in Organic Letters described a novel synthetic route utilizing this compound to produce derivatives with enhanced pharmacological properties. The researchers employed a combination of solid-phase synthesis and click chemistry to generate a library of ethane-1,1,2-tricarboxylic acid derivatives, which were subsequently screened for antimicrobial activity. Several derivatives exhibited potent activity against Gram-positive bacteria, underscoring the potential of this compound in antibiotic development.

Despite these advancements, challenges remain in the application of ethane-1,1,2-tricarboxylic acid in clinical settings. Issues such as bioavailability, toxicity, and metabolic stability need to be addressed through further research. Recent efforts have focused on structural modifications to improve these properties. For instance, a 2023 study in ACS Chemical Biology reported the development of prodrugs based on ethane-1,1,2-tricarboxylic acid, which demonstrated improved pharmacokinetic profiles in preclinical models. These findings pave the way for future translational studies.

In conclusion, ethane-1,1,2-tricarboxylic acid (CAS: 922-84-9) represents a versatile compound with significant potential in chemical biology and medicine. Recent research has elucidated its roles in enzyme inhibition, metal chelation, and as a synthetic precursor, highlighting its broad applicability. However, further studies are needed to overcome existing limitations and fully realize its therapeutic potential. This research brief underscores the importance of continued investigation into this promising molecule.

• 72604-79-6((R)-2-(Hydroxymethyl)butanoic acid)
• 616-62-6(2-Propylmalonic acid)
• 10097-02-6(2,2-Bis(hydroxymethyl)butanoic acid)
• 5660-81-1(Cyclopentylmalonic acid)
• 24779-68-8(2-(adamantan-1-yl)propanedioic acid)
• 534-59-8(Butylmalonic acid)
• 598-10-7(Cyclopropane-1,1-dicarboxylic acid)
• 601-79-6(2-Isopropylmalonic Acid)
• 1636-27-7(2,2-Dipropylmalonic Acid)
• 601-75-2(Ethylmalonic acid)